Prosecution Insights
Last updated: November 12, 2026
Application No. 18/604,472

COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS

Non-Final OA §102
Filed
Mar 13, 2024
Priority
Sep 16, 2021 — provisional 63/244,775 +2 more
Examiner
SZNAIDMAN, MARCOS L
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Lomond Therapeutics Inc.
OA Round
1 (Non-Final)
38%
Grant Probability
At Risk
1-2
OA Rounds
54%
With Interview

Examiner Intelligence

Grants only 38% of cases
38%
Career Allowance Rate
479 granted / 1279 resolved
-22.5% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
88 currently pending
Career history
1354
Total Applications
across all art units

Office Action

§102
ddNotice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is in response to applicant’s reply filed on June 3, 2026. Status of Claims Claims 13, 15-18 and 21-23 are currently pending and are the subject of this office action. Claims 13, 15-18 and 21-23 are presently under examination. Priority The present application is a 371 of PCT/US22/42431 filed on 09/02/2022 and claims priority to provisional application No. 63/244,775 filed on 09/16/2021. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 13, 15-18 and 21-23 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Fang et. al. (WO 2022/253252, December 8, 2022, priority data 06/03/21). For claim 13, Fang discloses the following compound: PNG media_image1.png 64 480 media_image1.png Greyscale (see page 165, fifth compound from the top), which corresponds to the following structure: PNG media_image2.png 110 168 media_image2.png Greyscale (this compound is identical to the compound on claim 13 (page 22 of the clean version, third row from the top, middle compound). For claim 15, Fang teaches pharmaceutical compositions of the above compound (see abstract for example). For claim 16, Fang teaches pharmaceutical compositions comprising one or more of the disclosed compounds (see abstract, see also claim 55). For claim 17, Fang teaches that the compounds are effective in inhibiting HPK1 (see claim 56). For claims 18 and 21-23, Fang teaches a method of treating cancer comprising the administration of the above compound, wherein the cancer can be breast cancer, cervical cancer, colon cancer, etc. (see claims 57 and 59). Conclusion No claims are allowed. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS L SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached Flexing M-F 7 AM-7 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on 571 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARCOS L SZNAIDMAN/ Primary Examiner, Art Unit 1628 June 18, 2026.
Read full office action

Prosecution Timeline

Mar 13, 2024
Application Filed
Aug 12, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773419
PHARMACOLOGICAL AGENTS FOR TREATING CONDITIONS OF THE EYE
3y 5m to grant Granted Oct 27, 2026
Patent 12758502
COMPOSITIONS AND METHODS OF USE
5y 8m to grant Granted Oct 13, 2026
Patent 12751949
Crystalline Forms of a BTK Inhibitor
4y 10m to grant Granted Oct 06, 2026
Patent 12751944
Methods and Compositions for Treating Fungal Infections
3y 11m to grant Granted Oct 06, 2026
Patent 12734146
Cobalt-Porphyrin Complexes for the Inactivation of the Biological Activity of Opioids
4y 6m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
38%
Grant Probability
54%
With Interview (+16.1%)
Low
PTA Risk
Based on 1279 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month